{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T10:52:04Z","timestamp":1785581524062,"version":"3.56.0"},"reference-count":34,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background: Helicobacter pylori infection is associated with peptic ulcer disease, chronic gastritis, and gastric cancer. Classic triple therapy (CTT) has been widely used, but increasing antibiotic resistance has reduced its effectiveness. Objectives: To evaluate the effectiveness of CTT compared with alternative regimens and to summarize adverse events and adherence. Methods: We searched PubMed, Scopus, Web of Science, and Cochrane Library from January 2000 to March 2025. Randomized trials and observational studies assessing eradication rates were included. Two reviewers independently screened the studies, extracted data, and assessed bias using Cochrane RoB or the Newcastle\u2013Ottawa Scale. Outcomes included eradication rate, adverse events, and adherence. Results: Thirteen studies (n = 3490) were included. CTT eradication rates ranged from 61.9% to 88.8%. Sequential, bismuth-based quadruple and high-dose PPI regimens achieved higher rates (&gt;90% in several trials). Adverse events were mild\u2013moderate and most frequent in quadruple therapy, though adherence remained &gt;90%. Evidence certainty varied (moderate to low in most comparisons). Geographic variation in resistance limited generalizability. Conclusions: CTT is less effective in high-resistance regions. Quadruple, sequential, and high-dose PPI regimens provide superior outcomes. Region-specific treatment guided by susceptibility testing is recommended. Registration: Not registered.<\/jats:p>","DOI":"10.3390\/medicina61101745","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:05:13Z","timestamp":1758801913000},"page":"1745","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effectiveness of Classic Triple Therapy Compared with Alternative Regimens for Eradicating H. pylori: A Systematic Review"],"prefix":"10.3390","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2291-1254","authenticated-orcid":false,"given":"Majid","family":"Darraj","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, College of Medicine, Jazan University, Jazan 45142, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Reyes, V.E. (2023). Helicobacter pylori and Its Role in Gastric Cancer. Microorganisms, 11.","DOI":"10.3390\/microorganisms11051312"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1128\/CMR.00011-10","article-title":"Helicobacter pylori and Gastric Cancer: Factors That Modulate Disease Risk","volume":"23","author":"Wroblewski","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Ali, A., and AlHussaini, K.I. (2024). Helicobacter pylori: A Contemporary Perspective on Pathogenesis, Diagnosis and Treatment Strategies. Microorganisms, 12.","DOI":"10.3390\/microorganisms12010222"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"346","DOI":"10.5009\/gnl13451","article-title":"Helicobacter pylori Eradication within 120 Days Is Associated with Decreased Complicated Recurrent Peptic Ulcers in Peptic Ulcer Bleeding Patients","volume":"9","author":"Chang","year":"2015","journal-title":"Gut Liver"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11894-016-0509-x","article-title":"Eradication of Helicobacter pylori Infection","volume":"18","author":"Marcus","year":"2016","journal-title":"Curr. Gastroenterol. Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"437","DOI":"10.22516\/25007440.314","article-title":"Helicobacter pylori: \u00bfc\u00f3mo mejorar las terapias de erradicaci\u00f3n?","volume":"33","year":"2018","journal-title":"Rev. Colomb. Gastroenterol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3389\/fcimb.2017.00168","article-title":"Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance","volume":"7","author":"Hu","year":"2017","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/apt.13497","article-title":"Review article: The global emergence of Helicobacter pylori antibiotic resistance","volume":"43","author":"Thung","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"14542","DOI":"10.1038\/s41598-024-63982-0","article-title":"Prevalence of Helicobacter pylori resistance to certain antibiotics at An-Najah University Hospital: A cross-sectional study","volume":"14","author":"Abdoh","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"5252","DOI":"10.3748\/wjg.v20.i18.5252","article-title":"Attempts to enhance the eradication rate of Helicobacter pylori infection","volume":"20","author":"Bang","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Kim, S.Y., and Chung, J.-W. (2020). Best Helicobacter pylori Eradication Strategy in the Era of Antibiotic Resistance. Antibiotics, 9.","DOI":"10.3390\/antibiotics9080436"},{"key":"ref_12","first-page":"1134","article-title":"Bismuth-containing quadruple therapy for Helicobacter pylori","volume":"25","author":"Lu","year":"2013","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"104661","DOI":"10.1016\/j.micpath.2020.104661","article-title":"Efficacy and safety of bismuth-containing quadruple treatment and concomitant treatment for first-line Helicobacter pylori eradication: A systematic review and meta-analysis","volume":"152","author":"Guo","year":"2021","journal-title":"Microb Pathog."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.15419\/bmrat.v4i11.384","article-title":"Levofloxacin-based sequential therapy versus classic triple therapy in Helicobacter pylori eradication: A randomized clinical trial","volume":"4","author":"Sherkatolabbasieh","year":"2017","journal-title":"Biomed. Res. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"129","DOI":"10.15761\/ICM.1000129","article-title":"Eradication rate of Helicobacter pylori by classic triple therapy in Lebanon: Is it still effective?","volume":"2","author":"Hassan","year":"2018","journal-title":"Integr. Clin. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1096103","DOI":"10.3389\/fphar.2023.1096103","article-title":"14-day pantoprazole- and amoxicillin-containing high-dose dual therapy for Helicobacter pylori eradication in elderly patients: A prospective, randomized controlled trial","volume":"14","author":"Yang","year":"2023","journal-title":"Front. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3855\/jidc.911","article-title":"Clarithromycin-based triple therapy for Helicobacter pylori treatment in peptic ulcer patients","volume":"4","author":"Felga","year":"2010","journal-title":"J. Infect. Dev. Ctries."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"133","DOI":"10.5152\/UCD.2014.2678","article-title":"First-line therapy in Helicobacter pylori eradication therapy: Experience of a surgical clinic","volume":"30","author":"Ozbalci","year":"2014","journal-title":"Turk. J. Surg."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/hel.12041","article-title":"Improved Efficacy of Proton Pump Inhibitor\u2013Amoxicillin\u2013Clarithromycin Triple Therapy for Helicobacter pylori Eradication in Low Clarithromycin Resistance Areas or for Tailored Therapy","volume":"18","author":"Prasertpetmanee","year":"2013","journal-title":"Helicobacter"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1007\/s10620-016-4305-0","article-title":"Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance","volume":"61","author":"Matsumoto","year":"2016","journal-title":"Dig. Dis. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.12816\/0030878","article-title":"Effectiveness of 14-days course of clarithromycin-based triple therapy as first line therapy for h.pylori infection in egyptian elderly patients","volume":"2","author":"Salamah","year":"2015","journal-title":"EJGG"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1365-2125.2011.04048.x","article-title":"Effectiveness of three times daily lansoprazole\/amoxicillin dual therapy for Helicobacter pylori infection in Korea","volume":"73","author":"Kim","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cgh.2019.03.048","article-title":"Combination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More than 90% of Patients","volume":"18","author":"McNicholl","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.3748\/wjg.v20.i13.3615","article-title":"Rabeprazole, clarithromycin, and amoxicillin Helicobacter pylori eradication therapy: Report of an efficacy study","volume":"20","author":"Onyekwere","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"142","DOI":"10.4166\/kjg.2020.76.3.142","article-title":"Efficacy of Seven-day High-dose Esomeprazole-based Triple Therapy versus Seven-day Standard Dose Non-esomeprazole-based Triple Therapy as the First-line Treatment of Patients with Helicobacter pylori Infection","volume":"76","author":"Lee","year":"2020","journal-title":"Korean J. Gastroenterol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12879-023-07993-8","article-title":"Helicobacter pylori eradication rates using clarithromycin and levofloxacin-based regimens in patients with previous COVID-19 treatment: A randomized clinical trial","volume":"23","author":"Kamal","year":"2023","journal-title":"BMC Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1128\/AAC.44.8.2214-2216.2000","article-title":"Regional Differences in Metronidazole Resistance and Increasing Clarithromycin Resistance among Helicobacter pylori Isolates from Japan","volume":"44","author":"Kato","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1128\/JCM.39.1.394-397.2001","article-title":"High Levels of Resistance to Metronidazole and Clarithromycin in Helicobacter pylori Strains in Children","volume":"39","author":"Kalach","year":"2001","journal-title":"J. Clin. Microbiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1097\/MCG.0000000000001448","article-title":"Efficacy and Safety of Modified Dual Therapy as the First-line Regimen for the Treatment of Helicobacter pylori Infection","volume":"55","author":"Huang","year":"2021","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.3748\/wjg.v25.i34.5097","article-title":"Optimizing proton pump inhibitors in Helicobacter pylori treatment: Old and new tricks to improve effectiveness","volume":"25","author":"Ierardi","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1155\/2013\/801915","article-title":"Prolonged Treatment Duration is Required for Successful Helicobacter pylori Eradication with Proton Pump Inhibitor Triple Therapy in Canada","volume":"27","author":"Fallone","year":"2013","journal-title":"Can. J. Gastroenterol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Gisbert, J.P. (2020). Optimization Strategies Aimed to Increase the Efficacy of Helicobacter pylori Eradication Therapies with Quinolones. Molecules, 25.","DOI":"10.3390\/molecules25215084"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"107","DOI":"10.37349\/edd.2024.00043","article-title":"Helicobacter pylori and gastric cancer: A critical approach to who really needs eradication","volume":"3","author":"Kouroumalis","year":"2024","journal-title":"Explor. Dig. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s11938-020-00300-3","article-title":"Update on the Management of Helicobacter pylori Infection","volume":"18","author":"Saleem","year":"2020","journal-title":"Curr. Treat. Options Gastroenterol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/10\/1745\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:49:33Z","timestamp":1760035773000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/10\/1745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":34,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["medicina61101745"],"URL":"https:\/\/doi.org\/10.3390\/medicina61101745","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]}}}